Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 7 (July)

1. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
   Cancer Chemother Pharmacol, 58(4): 460-70. [Abstract] [Full-text]
2. Molecular targets and the treatment of myeloid leukemia.
   Mol Genet Metab, 88(3): 216-224. [Abstract] [Full-text]
3. Janus kinase 2: a critical target in chronic myelogenous leukemia.
   Cancer Res, 66(13): 6468-72. [Abstract] [Full-text]
4. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.
   Blood, 108(2): 678-84. [Abstract] [Full-text]
5. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
   Blood, 108(2): 645-52. [Abstract] [Full-text]
6. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
   Blood, 108(2): 697-704. [Abstract] [Full-text]
7. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
   Stem Cells, 24(7): 1814-21. [Abstract] [Full-text]
8. Human Glioblastoma and Carcinoma Xenograft Tumors Treated by Combined Radiation and Imatinib (Gleevec((R))).
   Strahlenther Onkol, 182(7): 400-407. [Abstract] [Full-text]
9. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.
   Biochem Biophys Res Commun, 347(1): 31-5. [Abstract] [Full-text]
10. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Leuk Res, 30(9): 1201-5. [Abstract] [Full-text]
11. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
    Leuk Res, 30(9): 1159-65. [Abstract] [Full-text]
12. Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity.
    J Cancer Res Clin Oncol, 132(9): 589-99. [Abstract] [Full-text]
13. Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
    Cancer Genet Cytogenet, 168(2): 120-3. [Abstract] [Full-text]
14. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
    Br J Clin Pharmacol, 62(1): 97-112. [Abstract] [Full-text]
15. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Histopathology, 49(1): 52-65. [Abstract] [Full-text]
16. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.
    Br J Haematol, 134(2): 171-9. [Abstract] [Full-text]
17. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
    Leukemia, 20(8): 1400-7. [Abstract] [Full-text]
18. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
    Proteomics. [Abstract] [Full-text]
19. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Ann Surg, 244(2): 176-84. [Abstract] [Full-text]
20. Novel combinations based on epidermal growth factor receptor inhibition.
    Clin Cancer Res, 12(14): 4446s-4450s. [Abstract] [Full-text]
21. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases.
    Br J Radiol, 79(944): e40-4. [Abstract] [Full-text]
22. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.
    Biol Blood Marrow Transplant, 12(8): 795-807. [Abstract] [Full-text]
23. Everolimus alters imatinib blood partition in favour of the erythrocyte.
    J Pharm Pharmacol, 58(8): 1063-6. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.